Gilead Sciences Inc’s antiviral remdesivir could be priced up to $5,080 per course
- 4 years ago
Covid-19 updates: Gilead Sciences Inc’s antiviral remdesivir could be priced up to $5,080 per course
The first clinical trial of Covid-19 vaccine developed by the Oxford University has begun in South Africa.
The global fight against Covid-19 pandemic is intensifying with medical experts and drugmakers from across the world ramping up effort to arrive at the potential coronavirus vaccine and treatment.
With nearly 10 million Covid-19 patients across the globe and over 4.8 coronavirus fatalities, the virus has almost the entire planet under its grip and the need for a Covid-19 antidote becomes more urgent by the day.
American biopharmaceutical company Gilead Sciences has said it will soon start clinical trials for an inhaled formulation of its antiviral drug remdesivir used for the treatment of Covid-19. Remdesivir has made great strides in its role in the formulation of a vaccine against the contagion.
Here are the latest development on Covid-19 vaccine and treatment:
The first clinical trial of Covid-19 vaccine developed by the Oxford University has begun in South Africa.
The global fight against Covid-19 pandemic is intensifying with medical experts and drugmakers from across the world ramping up effort to arrive at the potential coronavirus vaccine and treatment.
With nearly 10 million Covid-19 patients across the globe and over 4.8 coronavirus fatalities, the virus has almost the entire planet under its grip and the need for a Covid-19 antidote becomes more urgent by the day.
American biopharmaceutical company Gilead Sciences has said it will soon start clinical trials for an inhaled formulation of its antiviral drug remdesivir used for the treatment of Covid-19. Remdesivir has made great strides in its role in the formulation of a vaccine against the contagion.
Here are the latest development on Covid-19 vaccine and treatment: